Literature DB >> 31633432

Illness Understanding and Advance Care Planning in Patients with Advanced Lymphoma.

Kelly M Trevino1, Sarah C Rutherford2,3, Chrystal Marte1, Daniel Jie Ouyang2,3, Peter Martin2,3, Holly G Prigerson2,3, John P Leonard2,3.   

Abstract

Background: The prognosis of an aggressive lymphoma can change dramatically following failure of first-line treatment. This sudden shift is challenging for the promotion of illness understanding and advance care planning (ACP). Yet, little is known about illness understanding and ACP in patients with aggressive lymphomas. Objective: To examine illness understanding, rates of engagement in ACP, and reasons for lack of ACP engagement in patients with advanced B cell lymphomas. Design: Cross-sectional observational study. Setting/Subjects: Patients (n = 27) with aggressive B cell lymphomas that relapsed after first- or second-line treatment treated at a single urban academic medical center. Measurements: Participants were administered structured surveys by trained staff to obtain self-report measures of illness understanding (i.e., aggressiveness, terminality, curability) and ACP (i.e., discussions of care preferences, completion of advance directives).
Results: The majority of patients reported discussing curability (92.6%), prognosis (77.8%), and treatment goals (88.9%) with their medical team. Yet, less than one-third of patients reported being terminally ill (29.6%) and having incurable disease (22.2%). Most patients had a health care proxy (81.5%) and had decided about do-not-resuscitate status (63%), but the majority had not completed a living will (65.4%) or discussed their care preferences with others (55.6%). Conclusions: The accuracy of lymphoma patients' illness understanding following first-line treatment is difficult to determine due to the potential for cure following transplant. However, this study suggests that a large proportion of patients with advanced B cell lymphomas may underestimate the severity of their illness, despite discussing illness severity with their medical team. Providing patients with information on prognosis, and the ACP process may increase engagement in ACP.

Entities:  

Keywords:  B cell lymphoma; advance care planning; illness understanding

Year:  2019        PMID: 31633432      PMCID: PMC7249459          DOI: 10.1089/jpm.2019.0311

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  34 in total

1.  Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.

Authors:  Michael Crump; Sattva S Neelapu; Umar Farooq; Eric Van Den Neste; John Kuruvilla; Jason Westin; Brian K Link; Annette Hay; James R Cerhan; Liting Zhu; Sami Boussetta; Lei Feng; Matthew J Maurer; Lynn Navale; Jeff Wiezorek; William Y Go; Christian Gisselbrecht
Journal:  Blood       Date:  2017-08-03       Impact factor: 22.113

2.  Cancer patient expectations of and communication with oncologists and oncology nurses: the experience of an integrated oncology and palliative care service.

Authors:  R Sapir; R Catane; B Kaufman; R Isacson; A Segal; S Wein; N I Cherny
Journal:  Support Care Cancer       Date:  2000-11       Impact factor: 3.603

3.  Associations among prognostic understanding, quality of life, and mood in patients with advanced cancer.

Authors:  Areej El-Jawahri; Lara Traeger; Elyse R Park; Joseph A Greer; William F Pirl; Inga T Lennes; Vicki A Jackson; Emily R Gallagher; Jennifer S Temel
Journal:  Cancer       Date:  2013-10-10       Impact factor: 6.860

4.  Experiences and attitudes of patients with terminal cancer and their family caregivers toward the disclosure of terminal illness.

Authors:  Young Ho Yun; Yong Chol Kwon; Myung Kyung Lee; Woo Jin Lee; Kyung Hae Jung; Young Rok Do; Samyong Kim; Dae Seog Heo; Jong Soo Choi; Sang Yoon Park
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

5.  Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care.

Authors:  Jennifer S Temel; Joseph A Greer; Sonal Admane; Emily R Gallagher; Vicki A Jackson; Thomas J Lynch; Inga T Lennes; Connie M Dahlin; William F Pirl
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

6.  It Is Not What You Think: Associations Between Perceived Cognitive and Physical Status and Prognostic Understanding in Patients With Advanced Cancer.

Authors:  Keiko Kurita; Eugenia L Siegler; M Cary Reid; Renee C Maciejewski; Holly G Prigerson
Journal:  J Pain Symptom Manage       Date:  2018-05-10       Impact factor: 3.612

7.  Relationship between cancer patients' predictions of prognosis and their treatment preferences.

Authors:  J C Weeks; E F Cook; S J O'Day; L M Peterson; N Wenger; D Reding; F E Harrell; P Kussin; N V Dawson; A F Connors; J Lynn; R S Phillips
Journal:  JAMA       Date:  1998-06-03       Impact factor: 56.272

Review 8.  Communication in end-stage cancer: review of the literature and future research.

Authors:  Elizabeth D Trice; Holly G Prigerson
Journal:  J Health Commun       Date:  2009

Review 9.  When and why should patients with hematologic malignancies see a palliative care specialist?

Authors:  Thomas W LeBlanc; Areej El-Jawahri
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2015

10.  Preferred and actual place of death in haematological malignancy.

Authors:  D A Howell; H I Wang; E Roman; A G Smith; R Patmore; M J Johnson; A Garry; M Howard
Journal:  BMJ Support Palliat Care       Date:  2015-07-08       Impact factor: 3.568

View more
  2 in total

Review 1.  Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas.

Authors:  Oreofe O Odejide
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 2.  Goal of a "Good Death" in End-of-Life Care for Patients with Hematologic Malignancies-Are We Close?

Authors:  Thomas M Kuczmarski; Oreofe O Odejide
Journal:  Curr Hematol Malig Rep       Date:  2021-04-16       Impact factor: 3.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.